Implementation of Innovative Treatment for Moral Injury Syndrome: A Hybrid Type 2 Study
1 other identifier
interventional
200
1 country
5
Brief Summary
Moral Injury Syndrome (MIS) affects up to 35-60% of Veterans managing combat-related PTSD; it results from experiences that challenge deeply held values or spiritual beliefs. Symptoms of MIS may include hopelessness, helplessness, loss of spiritual beliefs, difficulty with forgiveness, loss of meaning or purpose, reduced trust in self or others, or intractable guilt, shame or anger. Veterans managing MIS have difficulty responding to mental health treatment, and are at increased risk for suicide ideation or attempts. To date evidence-based interventions for MIS are not widely available in VA. This study will implement an evidence-based intervention for MIS in four VA facilities, collect data on the effectiveness of the intervention, and develop an implementation toolkit. This data will inform national dissemination in collaboration with the Office of Mental Health and Suicide Prevention and the National Chaplain Service.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jul 2024
Longer than P75 for not_applicable
5 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 19, 2024
CompletedFirst Posted
Study publicly available on registry
January 30, 2024
CompletedStudy Start
First participant enrolled
July 30, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 31, 2028
July 4, 2025
July 1, 2025
3.4 years
January 19, 2024
July 3, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
Change in Moral Injury and Distress Scale
Full Scale Name: Moral Injury and Distress Scale Score Range: 0-90, with higher scores indicating more symptoms.
8 weeks (end of treatment) and 20 weeks (long-term follow-up)
Change in Moral Injury Outcomes Scale
Full Scale Name: Moral Injury and Distress Scale Score Range: 0-56, with higher scores indicating more symptoms.
8 weeks (end of treatment) and 20 weeks (long-term follow-up)
Change in Expressions of Moral Injury Scale
Full Scale Name: Expressions of Moral Injury Scale Score Range: 10-100, with higher scores indicating more symptoms.
8 weeks (end of treatment) and 20 weeks (long-term follow-up)
Change in Religious and Spiritual Struggles Scale
Full Scale Name: Religions and Spiritual Struggles Scale Score Range: 0=4 with higher scores indicating more symptoms
8 weeks (end of treatment) and 20 weeks (long-term follow-up)
Secondary Outcomes (7)
Change in Patient Health Questionnaire-9
8 weeks (end of treatment) and 20 weeks (long-term follow-up)
Change in Sheehan Disability Scale
8 weeks (end of treatment) and 20 weeks (long-term follow-up)
Change in Inventory of Community Participation
8 weeks (end of treatment) and 20 weeks (long-term follow-up)
Change in Beck Scale for Suicide Ideation
8 weeks (end of treatment) and 20 weeks (long-term follow-up)
Change in Reasons for Living Inventory
8 weeks (end of treatment) and 20 weeks (long-term follow-up)
- +2 more secondary outcomes
Study Arms (2)
Building Spiritual Strength
EXPERIMENTALSpiritually integrated group intervention for moral injury.
Present Centered Group Therapy
ACTIVE COMPARATORCoping strategies group intervention addressing broad spectrum trauma symptoms
Interventions
Spiritually Integrated group intervention for moral injury
Active control, manualized evidence-based coping skills intervention for PTSD
Eligibility Criteria
You may qualify if:
- Veteran status and:
- (a) validation of any of the first three items on the Moral Injury and Distress Scale, which is consistent with probable MIS
- (b) willingness to be randomized to either treatment condition
- (c) stability on mental health medications for at least 8 weeks
- (d) age of 18 years or older
You may not qualify if:
- (a) insufficient capacity to consent
- (b) active psychosis or substance use at levels that would interfere with treatment, assessed via chart review, the Alcohol Use Disorders Identification Test - Concise (AUDIT-C) score, and the Mini International Neuropsychiatric Interview (MINI)
- (c) currently involved in evidence-based psychotherapy for MIS, or evidence-based psychotherapy for PTSD, assessed via chart review and intake interview
- (d) managing any severe psychopathology that, in the opinion of the investigative team, requires immediate clinical attention, such as imminent suicide risk, assessed via the MINI and supplemental homicide risk questions.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- VA Office of Research and Developmentlead
- VA Central Alabama Health Care Systemcollaborator
- VA Atlanta Healthcare Systemcollaborator
- Michael E. DeBakey VA Medical Centercollaborator
- Minneapolis Veterans Affairs Medical Centercollaborator
Study Sites (5)
Central Arkansas Veterans Healthcare System , Little Rock, AR
Little Rock, Arkansas, 72205, United States
Atlanta VA Medical and Rehab Center, Decatur, GA
Decatur, Georgia, 30033-4004, United States
Maine VA Medical Center, Augusta, ME
Augusta, Maine, 04330, United States
Minneapolis VA Health Care System, Minneapolis, MN
Minneapolis, Minnesota, 55417-2309, United States
Michael E. DeBakey VA Medical Center, Houston, TX
Houston, Texas, 77030-4211, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jeanette Irene Harris, PhD MS MS
Maine VA Medical Center, Augusta, ME
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Masking Details
- Outcomes assessor will not have access to shared files, and will not be at any team meetings in which individual participants are discussed, so she will not know to what condition the participants have been assigned.
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- PARALLEL
- Sponsor Type
- FED
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 19, 2024
First Posted
January 30, 2024
Study Start
July 30, 2024
Primary Completion (Estimated)
January 1, 2028
Study Completion (Estimated)
July 31, 2028
Last Updated
July 4, 2025
Record last verified: 2025-07
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
- Time Frame
- Study protocols will be shared across all sites in preparation for data collection across sites; individual sites will not be permitted to collect any data until they have met with lead site personnel in Maine for instruction and review of study procedures. The independent evaluator will be located in Maine; other sites will be expected to transmit IPD for participants scheduled for assessments within the 14 days preceding anticipated date of assessment. Data analysis will take place in Little Rock. When data collected at each individual site is complete for each Aim, the site will transmit their data to the lead statistician in Little Rock. The lead statistician may or may not transmit part or all of the data to the assistant statistician in Maine for assistance with the analysis.
- Access Criteria
- Only the study team will have access to this data during the study. Should the investigators receive a request for access to the data after the completion of the study, the investigators will consult with the IRB and the Privacy Officer, and if approved, share a de-identified data set as needed for verification of the research.
Sites involved in this study may share IPD via a) secure, VA approved videoconferencing, b) telephone, c) secure, VA approved electronic data sharing, and d) encrypted e-mail.